Sovaldi (sofosbuvir) / Gilead 
Welcome,         Profile    Billing    Logout  
 18 Diseases   22 Trials   22 Trials   2501 News 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sovaldi (sofosbuvir) / Gilead
ACTRN12620000794909: An efficacy study of combined oral doses of glecaprevir/pibrentasvir and sofosbuvir for 16 weeks in hepatitis C patients with documented NS5A resistance who did not respond to previous treatment

Not yet recruiting
4
75
 
Auckland District Health Board, Auckland District Health Board
Hepatitis C
 
 
2014-004134-26: A multicenter prospective study on the cost / benefit / safety of Sofosbuvir administered to patients with chronic hepatitis C virus and Mixed Cryoglobulinemia Studio prospettico a cui aderiscono più centri che valuta i costi/benefici/sicurezza del farmaco Sofosbuvir somministrato a pazienti affetti da epatite cronica da virus C e Crioglobulinemia Mista

Ongoing
4
30
Europe
Tablet, Sovaldi
Centro Masve -Università degli Studi di Firenze-AOUC, Gilead Sciences Int, Ltd.
HCV chronic hepatitis and Mixed Cryoglobulinemia Epatite cronica HCV correlata e Sindrome Crioglobulinemica, Patients with chronic hepatitis by hepatitis virus C and mixed cryoglobulinemia Paziente affetto da epatite cronica da virus C e crioglubulinemia mista, Diseases [C] - Virus Diseases [C02]
 
 
ChiCTR1900023342: A phase IV Study to Evaluate the Safety and Effectiveness of Sofosbuvir-containing Treatment Regimens in Patients with Chronic Hepatitis C Virus (HCV) Infection in a Chinese Real-World Setting

Recruiting
4
3000
 
Case series
Beijing Tsinghua Changgung Hospital; Gilead Sciences Shanghai Pharmaceutical Technology., Ltd, Gilead Sciences Shanghai Pharmaceutical Technology.,Ltd
HCV
 
 
STRIVE-4, NCT03855917: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

Recruiting
4
30
RoW
Sofosbuvir 400mg [Sovaldi], Sovaldi, Glecaprevir/pibrentasvir (300mg/120mg), Maviret
Kirby Institute
Hepatitis C
02/26
02/26
NCT03444272: Effect of Direct-acting Antiviral Drugs on Erectile Function

Recruiting
3
105
RoW
Sofosbuvir and Daklatasuvir, Sofaldy, mpiviropack, daklanork
Sherief Abd-Elsalam, Benha University
Hepatitis C
12/22
12/22
NCT04497649: Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

Recruiting
2/3
100
RoW
Sofosbuvir, Mpiviropack, Sovaldy, soflanork, Daclatasvir, daklinza, daklanork
Tanta University
Covid19
04/21
04/21
NCT04460443: Sofosbuvir in Treatment of COVID 19

Recruiting
2/3
60
RoW
sofosbuvir, Mpiviropack, Sovaldy, soflanork, Sofosbuvir ledipsavir, mpiviropack plus, Daclatasvir, daklinza
Tanta University
COVID
08/21
08/21
REVOLUTIOn, NCT04468087: Antiviral Agents Against COVID-19 Infection

Completed
2/3
256
RoW
Atazanavir, Active Group, Daclatasvir 60 mg, Sofusbuvir + Daclastavir 60 mg, Placebo Atazanavir, Placebo group, Placebo Daclatasvir 60 mg, Placebo Sofusbuvir + Daclatasvir 60 mg
Hospital do Coracao
COVID-19
08/21
08/21
NCT04885855: 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Recruiting
2/3
316
RoW
Sofosbuvir 400 MG, Grateziano, Ravidasvir 200mg, PPI-668
Muhammad Radzi Abu Hassan
Hepatitis C
10/22
12/22
IRCT20200328046882N1: Efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2: An Open Label phase II Trial

Recruiting
2
0
Tehran
Sovaldi (sofosbuvir) - Gilead
Gilead
SARS-CoV-2 َassociated SARI
 
 
2018-003640-23: PHASE II CLINICAL STUDY ON THE USE OF HCV+ DONORS FOR SOLID ORGAN TRANSPLANTATION. STUDIO CLINICO DI FASE II PER L'UTILIZZO DI DONATORI HCV+ A SCOPO DI TRAPIANTO.

Ongoing
2
212
Europe
EPCLUSA SOFOSBUVIR 400MG/VELPATASVIR 100MG, [1BV30D], Film-coated tablet, EPCLUSA
ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT
USE OF POSITIVE DONORS FOR INFECTION OF THE HEPATITIS VIRUS FOR THE TRANSPLANTATION OF SOLID ORGANS IN AN ENDEMIC AREA FOR HEPATITIS C WITH LOW RATE OF DONATIONS FROM CADAVERS: OPEN PHASE II CLINICAL STUDY. UTILIZZO DI DONATORI POSITIVI PER INFEZIONE DEL VIRUS DELL’EPATITE C PER IL TRAPIANTO DI ORGANI SOLIDI IN UN’AREA ENDEMICA PER EPATITE C CON BASSO TASSO DI DONAZIONI DA CADAVERE: STUDIO CLINICO MONOCENTRICO APERTO DI FASE II., HCV- patient to whom an organ from a HCV+ donor is transplanted who will receive Epclusa. Pazienti HCV- a cui venga trapiantato un organo da donatore HCV+ che verranno trattati con Epclusa., Diseases [C] - Digestive System Diseases [C06]
 
 
ChiCTR1800017298: Pharmacokinetics study of sofosbuvir tablets in healthy Chinese subjects

Recruiting
1
48
 
After the subjects were fasted for at least 10 h, each group received a low dose (400 mg, 1 tablet) ;After the subjects were fasted for at least 10 h, each group fed a low-dose oral dose (400 mg, 1 tablet) ;After the subjects were fasted for at least 10 h, each group received a high dose (800 mg, 2 tablets) ;Continuous administration for 8 days, low dose (400 mg) on an empty stomach every morning
The Third Hospital of Changsha; Nanjing ChiaTai TianQing Pharmaceuticals LP, self-raised
Chronic hepatitis C.
 
 
ChiCTR-IOR-17013516: Human Bioequivalence Trial of Sofosbuvir Tablets

Recruiting
N/A
96
 
sofosbuvir tablet administered once under fasting condition, 400 mg ;sofosbuvir tablet (Gilead) administered once under fasting condition, 400 mg ;sofosbuvir tablet administered once under fed condition, 400 mg ;sofosbuvir tablet (Gilead) administered once under fed condition, 400 mg
the Third Hospital of Changsha; Nanjing ChiaTai TianQing Pharmaceuticals LP, self-raised
Chronic hepatitis C.
 
 
ChiCTR1800016633: Human Bioequivalence Trial of Sofosbuvir Tablets

Recruiting
N/A
104
 
Fasting test preparations Sofosbuvir tablets(1dose, 400 mg) ;Fasting to Reference Preparation Sofosbuvir (1 dose, 400 mg) ;Postprandial test preparation of sofbuvir tablets (1 dose, 400mg) ;Postprandial reference preparation of soflobuvir(1 dose, 400 mg)
The Third Hospital of Changsha; Nanjing ChiaTai TianQing Pharmaceuticals LP, self-raised
Chronic hepatitis C
 
 
SCALE-C, NCT03776760: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination

Recruiting
N/A
600
RoW
Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, Epclusa, glecaprevir/pibrentasvir, Maviret
Kirby Institute, South Australian Health and Medical Research Institute, Flinders University
Hepatitis C, Hepatitis, Liver Diseases, Hepatitis, Viral, Human, RNA Virus Infections, Digestive System Diseases
08/22
08/22
LONGHEAD, NCT03042520: Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment

Recruiting
N/A
200
RoW
Observation only
Kaohsiung Medical University Chung-Ho Memorial Hospital, Chang Gung Memorial Hospital, National Taiwan University Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital, China Medical University, China, Mackay Memorial Hospital, Taipei Veterans General Hospital, Taiwan, Changhua Christian Hospital, Pusan National University Hospital, Asan Medical Center, Korea University, Inje University, Korea University Guro Hospital, Kyungpook National University Hospital, Seoul National University Hospital, Severance Hospital, Samsung Medical Center, Seoul National University Bundang Hospital, Soon Chun Hyang University, Seoul St. Mary's Hospital, Gachon University Gil Medical Center, Dong-A University Hospital, Gangnam Severance Hospital
Liver Fibroses, HepatoCellular Carcinoma, Cryoglobulinemia, Metabolic Disease, Diabetes Mellitus
09/22
09/22
NCT04122066: the Pulmonary Safety of Antihepatitis C Treatment

Not yet recruiting
N/A
50
NA
sofosbuvir \daclatsvir, Sovaldi\Daklinza
Assiut University
Hepatitis C
12/22
12/23
TOPIC, NCT03981211: Treatment of HOsPitalised Inpatients for Hepatitis C (): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

Recruiting
N/A
60
RoW
Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
Kirby Institute
Hepatitis C, Liver Inflammation, Liver Cirrhoses
02/25
02/25
EHCUS, NCT05503979: Elimination of Hepatitis C Virus Among Users of Substances

Not yet recruiting
N/A
1000
NA
Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa], Epclusa
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Gilead Sciences
Hepatitis C in Substance Users
08/23
05/24
NCT05248919: Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan

Enrolling by invitation
N/A
318
RoW
Epclusa (nucleotide HCV NS5B polymerase inhibitors)., Sofosbuvir 400 Mg and Velpatasvir 100 Mg Oral Capsules
Queen Mary University of London, Aga Khan University, Dow University of Health Sciences, University of Oxford, University of Bristol
Hepatitis C
09/25
09/25
ChiCTR2400088566: To evaluate colopivir hydrochloride capsules in combination with sofosbuvir tablets for the treatment of chronic HCV in the real world Safety and efficacy studies in infected patients

Not yet recruiting
N/A
100
 
Oral antiviral
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Beijing Keyingling Biotechnology Co., LTD
Patients with chronic HCV infection with or without cirrhosis
 
 
NCT05601518: Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.

Not yet recruiting
N/A
450
RoW
Beijing Tsinghua Chang Gung Hospital
Hepatitis C Infection
12/23
12/23

Download Options